Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 7/20 | 0.64 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.64 |
| ▸ | PDE4A | P27815 | 3/20 | 0.58 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.58 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.58 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.38 |
| ▸ | HBB | P68871 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quinazoline SCHEMBL16416421 | 0.79 | EGFR (0.47) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL618977 | 0.78 | ADORA2B (0.64) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL28516221 | 0.78 | ADORA2B (0.64) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL9574927 | 0.78 | ADORA2B (0.64) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL2837684 | 0.78 | ADORA2B (0.64) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL28648091 | 0.78 | ADORA2B (0.64) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL447390 | 0.78 | ADORA2B (0.64) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| 1-Methylxanthine SCHEMBL10996 | 0.78 | ADORA2B (1.00) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| SCHEMBL5510062 | 0.78 | ADORA2B (0.64) | ADORA2BADORA2APDE4APDE4BPDE4C | |
| 1-Methylxanthine SCHEMBL9682658 | 0.76 | ADORA2B (0.96) | ADORA2BADORA2APDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2935266-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF LINAGLIPTIN | Mylan Laboratories Ltd. (IN) | 2015-10-28 | — | — | EP | claimed |
| US-20150299200-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF LINAGLIPTIN | MYLAN LABORATORIES LTD (IN) | 2015-10-22 | — | — | US | claimed |
| WO-2014097314-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF LINAGLIPTIN | MYLAN LABORATORIES LTD (IN) | 2014-06-26 | — | — | WO | claimed |
| US-20160304520-A1 | An improved process for preparing Linagliptin and its key Intermediates | WOCKHARDT LTD (IN) | 2016-10-20 | — | — | US | disclosed |
| EP-2935266-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF LINAGLIPTIN | Mylan Laboratories Ltd. (IN) | 2015-10-28 | — | — | EP | disclosed |
| US-20150299200-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF LINAGLIPTIN | MYLAN LABORATORIES LTD (IN) | 2015-10-22 | — | — | US | disclosed |
| WO-2015011609-A1 | PROCESS FOR THE PREPARATION OF LINAGLIPTIN AND AN INTERMEDIATE THEREOF | RANBAXY LABORATORIES LIMITED (IN) | 2015-01-29 | — | — | WO | disclosed |
| WO-2015004599-A1 | AN IMPROVED PROCESS FOR PREPARING LINAGLIPTIN AND ITS KEY INTERMEDIATES | WOCKHARDT LIMITED (IN) | 2015-01-15 | — | — | WO | disclosed |
| WO-2014097314-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF LINAGLIPTIN | MYLAN LABORATORIES LTD (IN) | 2014-06-26 | — | — | WO | disclosed |
| US-20120165525-A1 | PROCESS FOR THE PREPARATION OF LINAGLIPTIN | DIPHARMA FRANCIS S.R.L. (IT) | 2012-06-28 | — | — | US | disclosed |
| EP-2468749-A1 | Process for the preparation of Linagliptin | Dipharma Francis S.r.l. (IT) | 2012-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165525-A1 | PROCESS FOR THE PREPARATION OF LINAGLIPTIN | DPP4, DPP8, DPP7 | ADORA2B 712/4885ADORA2A 785/4885PDE4A 679/4885 |
| US-20160304520-A1 | An improved process for preparing Linagliptin and its key Intermediates | DPP4, LCT, DPP3 | ADORA2B 1797/4885ADORA2A 3013/4885PDE4A 537/4885 |
| US-20150299200-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF LINAGLIPTIN | DPP4, DPP3, DPP8 | ADORA2B 1759/4885ADORA2A 2758/4885PDE4A 400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.